Skip to main content
Top
Published in: Clinical Rheumatology 10/2020

01-10-2020 | Ultrasound | Original Article

Enthesitis and joint erosions are disease traits associated with cardiovascular risk in psoriatic arthritis

Authors: Andrés Lorenzo, Estefanía Pardo, Lilyan Charca, Marina Pino, Rubén Queiro

Published in: Clinical Rheumatology | Issue 10/2020

Login to get access

Abstract

Aim

To analyze the prevalence of subclinical atherosclerosis (SA), as well as the factors associated with it, in psoriatic arthritis (PsA).

Methods

This cross-sectional observational study included 140 consecutive patients with PsA. Systematic COronary Risk Evaluation (SCORE) risk charts and carotid ultrasound (CU) were used to estimate cardiovascular risk (CVR). The presence of plaque and/or a carotid intima-media thickness (cIMT) > 0.9 mm defined SA. Disease features associated with SA were analyzed.

Results

The prevalence of SA in this study was 25%. According to the SCORE charts, 42.8%, 35.7%, and 21.5%, had low, moderate, and high-very high CVR, respectively. The best criterion to define a high CVR (by SCORE plus carotid plaques) corresponded to a cIMT > 0.63 mm (area under the ROC curve 0.75 (0.66–0.82), p < 0.0001). Patients in minimal disease activity (MDA) showed less SA (cIMT > 0.9 mm, 6.2% vs. 30.2% in non-MDA, p < 0.05, and carotid plaques in 23.7% vs. 32.6% in non-MDA). Disease factors associated with SA were age (OR 1.08 (1.03–1.13), p < 0.001), smoking (OR 4.26 (1.44–12.65), p = 0.01), enthesitis (OR 3.76 (1.36–10.40), p = 0.01), and erosive disease (OR 5.23 (1.33–20.50), p = 0.02).

Conclusions

Subclinical atherosclerosis was associated with both classic CVR factors as well as others more linked to the inflammatory nature of this disease. Patients reaching the MDA showed less SA. Cardiovascular risk should be closely monitored in PsA patients who develop enthesitis and/or structural damage.
Key Points
Subclinical atherosclerosis is relatively common in psoriatic arthritis.
Patients reaching the minimal disease activity response show less subclinical atherosclerosis.
Patients with enthesitis and/or structural damage are a high-risk population for subclinical atherosclerosis.
Literature
1.
go back to reference Ritchlin CT, Colbert RA, Gladman DD (2017) Psoriatic arthritis. New Engl J Med 376:957–970CrossRef Ritchlin CT, Colbert RA, Gladman DD (2017) Psoriatic arthritis. New Engl J Med 376:957–970CrossRef
2.
go back to reference Husni ME (2015) Comorbidities in psoriatic arthritis. Rheum Dis Clin N Am 41:677–698CrossRef Husni ME (2015) Comorbidities in psoriatic arthritis. Rheum Dis Clin N Am 41:677–698CrossRef
3.
go back to reference Scarpa R, Caso F, Costa L, Peluso R, Del Puente A, Olivieri I (2017) Psoriatic disease 10 years later. J Rheumatol 44:1298–1301CrossRef Scarpa R, Caso F, Costa L, Peluso R, Del Puente A, Olivieri I (2017) Psoriatic disease 10 years later. J Rheumatol 44:1298–1301CrossRef
4.
go back to reference Arida A, Protogerou AD, Kitas GD, Sfikakis PP (2018) Systemic inflammatory response and atherosclerosis: the paradigm of chronic inflammatory rheumatic diseases. Int J Mol Sci 19:E1890CrossRef Arida A, Protogerou AD, Kitas GD, Sfikakis PP (2018) Systemic inflammatory response and atherosclerosis: the paradigm of chronic inflammatory rheumatic diseases. Int J Mol Sci 19:E1890CrossRef
5.
go back to reference Lee KS, Kronbichler A, Eisenhut M, Lee KH, Shin JI (2018) Cardiovascular involvement in systemic rheumatic diseases: an integrated view for the treating physicians. Autoimmun Rev 17:201–214CrossRef Lee KS, Kronbichler A, Eisenhut M, Lee KH, Shin JI (2018) Cardiovascular involvement in systemic rheumatic diseases: an integrated view for the treating physicians. Autoimmun Rev 17:201–214CrossRef
6.
go back to reference Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peterset MJ et al (2017) EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 76:17–28CrossRef Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peterset MJ et al (2017) EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 76:17–28CrossRef
7.
go back to reference Castañeda S, Nurmohamed MT, González-Gay MA (2016) Cardiovascular disease in inflammatory rheumatic diseases. Best Pract Res Clin Rheumatol 30:851–869CrossRef Castañeda S, Nurmohamed MT, González-Gay MA (2016) Cardiovascular disease in inflammatory rheumatic diseases. Best Pract Res Clin Rheumatol 30:851–869CrossRef
8.
go back to reference Kerekes G, Soltész P, Nurmohamed MT, Gonzalez-Gay MA, Turiel M, Végh E, Shoenfeld Y, McInnes I, Szekanecz Z (2012) Validated methods for assessment of subclinical atherosclerosis in rheumatology. Nat Rev Rheumatol 8:224–234CrossRef Kerekes G, Soltész P, Nurmohamed MT, Gonzalez-Gay MA, Turiel M, Végh E, Shoenfeld Y, McInnes I, Szekanecz Z (2012) Validated methods for assessment of subclinical atherosclerosis in rheumatology. Nat Rev Rheumatol 8:224–234CrossRef
9.
go back to reference Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, CASPAR Study Group (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665–2673CrossRef Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, CASPAR Study Group (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665–2673CrossRef
10.
go back to reference Torre Alonso JC, Díaz Del Campo Fontecha P, Almodóvar R, Cañete JD, Montilla Morales C, Moreno M et al (2018) Recommendations of the Spanish Society of Rheumatology on treatment and use of systemic biological and non-biological therapies in psoriatic arthritis. Reumatol Clin 14:254–268CrossRef Torre Alonso JC, Díaz Del Campo Fontecha P, Almodóvar R, Cañete JD, Montilla Morales C, Moreno M et al (2018) Recommendations of the Spanish Society of Rheumatology on treatment and use of systemic biological and non-biological therapies in psoriatic arthritis. Reumatol Clin 14:254–268CrossRef
11.
go back to reference Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M, Huang F, Gu J, Khan MA, Kirazli Y, Maksymowych WP, Mielants H, Sørensen IJ, Ozgocmen S, Roussou E, Valle-Oñate R, Weber U, Wei J, Sieper J (2009) The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68:777–783CrossRef Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M, Huang F, Gu J, Khan MA, Kirazli Y, Maksymowych WP, Mielants H, Sørensen IJ, Ozgocmen S, Roussou E, Valle-Oñate R, Weber U, Wei J, Sieper J (2009) The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68:777–783CrossRef
12.
go back to reference Schoels MM, Aletaha D, Alasti F, Smolen JS (2016) Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis 75:811–818CrossRef Schoels MM, Aletaha D, Alasti F, Smolen JS (2016) Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis 75:811–818CrossRef
13.
go back to reference Coates LC, Fransen J, Helliwell PS (2010) Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 69:48–53CrossRef Coates LC, Fransen J, Helliwell PS (2010) Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 69:48–53CrossRef
14.
go back to reference Queiro R, Lorenzo A, Tejón P, Pardo E, Coto P, Ballina J (2019) Polyarticular evolution and late-onset psoriasis may be associated with cardiovascular disease in psoriatic arthritis. Int J Rheum Dis 22:269–274CrossRef Queiro R, Lorenzo A, Tejón P, Pardo E, Coto P, Ballina J (2019) Polyarticular evolution and late-onset psoriasis may be associated with cardiovascular disease in psoriatic arthritis. Int J Rheum Dis 22:269–274CrossRef
15.
go back to reference Sans S, Fitzgerald AP, Royo D, Conroy R, Graham I (2007) Calibrating the SCORE cardiovascular risk chart for use in Spain. Rev Esp Cardiol 60:476–485CrossRef Sans S, Fitzgerald AP, Royo D, Conroy R, Graham I (2007) Calibrating the SCORE cardiovascular risk chart for use in Spain. Rev Esp Cardiol 60:476–485CrossRef
16.
go back to reference Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, Csiba L, Desvarieux M, Ebrahim S, Hernandez Hernandez R, Jaff M, Kownator S, Naqvi T, Prati P, Rundek T, Sitzer M, Schminke U, Tardif JC, Taylor A, Vicaut E, Woo KS (2012) Mannheim carotid intima-media thickness and plaque consensus (2004-2006-2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European stroke conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. Cerebrovasc Dis 34:290–296CrossRef Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, Csiba L, Desvarieux M, Ebrahim S, Hernandez Hernandez R, Jaff M, Kownator S, Naqvi T, Prati P, Rundek T, Sitzer M, Schminke U, Tardif JC, Taylor A, Vicaut E, Woo KS (2012) Mannheim carotid intima-media thickness and plaque consensus (2004-2006-2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European stroke conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. Cerebrovasc Dis 34:290–296CrossRef
17.
go back to reference Gómez-Vaquero C, Corrales A, Zacarías A, Rueda-Gotor J, Blanco R, González-Juanatey C et al (2013) SCORE and REGICOR function charts underestimate the cardiovascular risk in Spanish patients with rheumatoid arthritis. Arthritis Res Ther 15:R91CrossRef Gómez-Vaquero C, Corrales A, Zacarías A, Rueda-Gotor J, Blanco R, González-Juanatey C et al (2013) SCORE and REGICOR function charts underestimate the cardiovascular risk in Spanish patients with rheumatoid arthritis. Arthritis Res Ther 15:R91CrossRef
18.
go back to reference Eder L, Chandran V, Gladman DD (2014) The Framingham risk score underestimates the extent of subclinical atherosclerosis in patients with psoriatic disease. Ann Rheum Dis 73:1990–1996CrossRef Eder L, Chandran V, Gladman DD (2014) The Framingham risk score underestimates the extent of subclinical atherosclerosis in patients with psoriatic disease. Ann Rheum Dis 73:1990–1996CrossRef
19.
go back to reference Torres T, Sales R, Vasconcelos C, Martins da Silva B, Selores M (2013) Framingham risk score underestimates cardiovascular disease risk in severe psoriatic patients: implications in cardiovascular risk factors management and primary prevention of cardiovascular disease. J Dermatol 40:923–926CrossRef Torres T, Sales R, Vasconcelos C, Martins da Silva B, Selores M (2013) Framingham risk score underestimates cardiovascular disease risk in severe psoriatic patients: implications in cardiovascular risk factors management and primary prevention of cardiovascular disease. J Dermatol 40:923–926CrossRef
20.
go back to reference Belur AD, Mehta NN (2018) Underestimation of risk of carotid subclinical atherosclerosis by cardiovascular risk scores in patients with psoriatic arthritis: how far are we from the truth? J Rheumatol 45:150–152CrossRef Belur AD, Mehta NN (2018) Underestimation of risk of carotid subclinical atherosclerosis by cardiovascular risk scores in patients with psoriatic arthritis: how far are we from the truth? J Rheumatol 45:150–152CrossRef
21.
go back to reference Cook NR, Paynter NP, Eaton CB, Manson JE, Martin LW, Robinson JG et al (2012) Comparison of the Framingham and Reynolds risk scores for global cardiovascular risk prediction in the multiethnic Women’s Health Initiative. Circulation 125:1748–1756CrossRef Cook NR, Paynter NP, Eaton CB, Manson JE, Martin LW, Robinson JG et al (2012) Comparison of the Framingham and Reynolds risk scores for global cardiovascular risk prediction in the multiethnic Women’s Health Initiative. Circulation 125:1748–1756CrossRef
22.
go back to reference Ikonomidis I, Makavos G, Katsimbri P, Boumpas DT, Parissis J, Iliodromitis E (2019) Imaging risk in multisystem inflammatory diseases. JACC Cardiovasc. Imaging 12:2517–2537 Ikonomidis I, Makavos G, Katsimbri P, Boumpas DT, Parissis J, Iliodromitis E (2019) Imaging risk in multisystem inflammatory diseases. JACC Cardiovasc. Imaging 12:2517–2537
23.
go back to reference Shen J, Lam SH, Shang Q, Wong CK, Li EK, Wong P, Kun EW, Cheng IT, Li M, Li TK, Zhu TY, Lee JJ, Chang M, Lee AP, Tam LS (2018) Underestimation of risk of carotid subclinical atherosclerosis by cardiovascular risk scores in patients with psoriatic arthritis. J Rheumatol 45:218–226CrossRef Shen J, Lam SH, Shang Q, Wong CK, Li EK, Wong P, Kun EW, Cheng IT, Li M, Li TK, Zhu TY, Lee JJ, Chang M, Lee AP, Tam LS (2018) Underestimation of risk of carotid subclinical atherosclerosis by cardiovascular risk scores in patients with psoriatic arthritis. J Rheumatol 45:218–226CrossRef
24.
go back to reference Martínez-Vidal MP, Fernández-Carballido C (2018) Is the SCORE chart underestimating the real cardiovascular (CV) risk of patients with psoriatic arthritis? Prevalence of subclinical CV disease detected by carotid ultrasound. Joint Bone Spine 85:327–332CrossRef Martínez-Vidal MP, Fernández-Carballido C (2018) Is the SCORE chart underestimating the real cardiovascular (CV) risk of patients with psoriatic arthritis? Prevalence of subclinical CV disease detected by carotid ultrasound. Joint Bone Spine 85:327–332CrossRef
25.
go back to reference Ibáñez-Bosch R, Restrepo-Velez J, Medina-Malone M, Garrido-Courel L, Paniagua-Zudaire I, Loza-Cortina E (2017) High prevalence of subclinical atherosclerosis in psoriatic arthritis patients: a study based on carotid ultrasound. Rheumatol Int 37:107–112CrossRef Ibáñez-Bosch R, Restrepo-Velez J, Medina-Malone M, Garrido-Courel L, Paniagua-Zudaire I, Loza-Cortina E (2017) High prevalence of subclinical atherosclerosis in psoriatic arthritis patients: a study based on carotid ultrasound. Rheumatol Int 37:107–112CrossRef
26.
go back to reference Corrales A, González-Juanatey C, Peiró ME, Blanco R, Llorca J, González-Gay MA (2014) Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study. Ann Rheum Dis 73:722–727CrossRef Corrales A, González-Juanatey C, Peiró ME, Blanco R, Llorca J, González-Gay MA (2014) Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study. Ann Rheum Dis 73:722–727CrossRef
27.
go back to reference Husted JA, Tom BD, Farewell VT, Schentag CT, Gladman DD (2007) A longitudinal study of the effect of disease activity and clinical damage on physical function over the course of psoriatic arthritis: does the effect change over time? Arthritis Rheum 56:840–849CrossRef Husted JA, Tom BD, Farewell VT, Schentag CT, Gladman DD (2007) A longitudinal study of the effect of disease activity and clinical damage on physical function over the course of psoriatic arthritis: does the effect change over time? Arthritis Rheum 56:840–849CrossRef
28.
go back to reference Kavanaugh A, van der Heijde D, Beutler A, Gladman D, Mease P, Krueger GG, McInnes I, Helliwell P, Coates LC, Xu S (2016) Radiographic progression of patients with psoriatic arthritis who achieve minimal disease activity in response to golimumab therapy: results through 5 years of a randomized, placebo-controlled study. Arthritis Care Res (Hoboken) 68:267–274CrossRef Kavanaugh A, van der Heijde D, Beutler A, Gladman D, Mease P, Krueger GG, McInnes I, Helliwell P, Coates LC, Xu S (2016) Radiographic progression of patients with psoriatic arthritis who achieve minimal disease activity in response to golimumab therapy: results through 5 years of a randomized, placebo-controlled study. Arthritis Care Res (Hoboken) 68:267–274CrossRef
29.
go back to reference Queiro R, Cañete JD, Montilla C, Abad M, Montoro M, Gómez S et al (2017) Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study. Arthritis Res Ther 19:72CrossRef Queiro R, Cañete JD, Montilla C, Abad M, Montoro M, Gómez S et al (2017) Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study. Arthritis Res Ther 19:72CrossRef
30.
go back to reference Eder L, Joshi AA, Dey AK, Cook R, Siegel EL, Gladman DD et al (2018) Association of tumor necrosis factor inhibitor treatment with reduced indices of subclinical atherosclerosis in patients with psoriatic disease. Arthritis Rheumatol 70:408–416CrossRef Eder L, Joshi AA, Dey AK, Cook R, Siegel EL, Gladman DD et al (2018) Association of tumor necrosis factor inhibitor treatment with reduced indices of subclinical atherosclerosis in patients with psoriatic disease. Arthritis Rheumatol 70:408–416CrossRef
31.
go back to reference Cheng IT, Shang Q, Li EK, Wong PC, Kun EW, Law MY et al (2019) Effect of achieving minimal disease activity on the progression of subclinical atherosclerosis and arterial stiffness: a prospective cohort study in psoriatic arthritis. Arthritis Rheumatol 71:271–280CrossRef Cheng IT, Shang Q, Li EK, Wong PC, Kun EW, Law MY et al (2019) Effect of achieving minimal disease activity on the progression of subclinical atherosclerosis and arterial stiffness: a prospective cohort study in psoriatic arthritis. Arthritis Rheumatol 71:271–280CrossRef
32.
go back to reference Shrestha A, Bahce-Altuntas A, Mowrey W, Broder A (2016) Active peripheral inflammation is associated with pro-atherogenic lipid profile in psoriatic arthritis. Semin Arthritis Rheum 46:286–290CrossRef Shrestha A, Bahce-Altuntas A, Mowrey W, Broder A (2016) Active peripheral inflammation is associated with pro-atherogenic lipid profile in psoriatic arthritis. Semin Arthritis Rheum 46:286–290CrossRef
33.
go back to reference von Stebut E, Reich K, Thaçi D, Koenig W, Pinter A, Körber A et al (2019) Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks. J Invest Dermatol 139:1054–1062CrossRef von Stebut E, Reich K, Thaçi D, Koenig W, Pinter A, Körber A et al (2019) Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks. J Invest Dermatol 139:1054–1062CrossRef
34.
go back to reference Gladman DD (2008) Mortality in psoriatic arthritis. Clin Exp Rheumatol 26(5 Suppl 51):S62–S65PubMed Gladman DD (2008) Mortality in psoriatic arthritis. Clin Exp Rheumatol 26(5 Suppl 51):S62–S65PubMed
Metadata
Title
Enthesitis and joint erosions are disease traits associated with cardiovascular risk in psoriatic arthritis
Authors
Andrés Lorenzo
Estefanía Pardo
Lilyan Charca
Marina Pino
Rubén Queiro
Publication date
01-10-2020
Publisher
Springer International Publishing
Published in
Clinical Rheumatology / Issue 10/2020
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-020-05088-2

Other articles of this Issue 10/2020

Clinical Rheumatology 10/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.